biostudies-literatureDe Maria RFPRC 5 per mille 2020 MURIRCC306https://www.ebi.ac.uk/biostudies/studies/S-EPMC12433426biostudies-literatureUnknown74(10)Advanced-stage sarcomas pose a major challenge in oncology, as they are often resistant to conventional therapies and associated with poor prognosis. CAR-based cellular immunotherapy is emerging as a very promising therapeutic option; however, clinically relevant animal models are urgently needed to accelerate the clinical development of these approaches. B7-H3 molecule, due to its low expression in normal tissue, high prevalence in multiple human cancers, and association with cancer stemness and aggressiveness, represents one of the most attractive targets for CAR-immunotherapy. In this study, we established a preclinical cellular immunotherapy platform based on canine cytokine-induced killer cells (CIK) redirected by an antihuman B7-H3 CAR against canine sarcoma cells and 3D sarcoma spheCancer immunology, immunotherapy : CIIDevelopment and activity of canine B7-H3-CAR.CIK lymphocytes against sarcomas: preclinical evidence and perspectives for human clinical translation.PMC12433426Ricerca Corrente 2024K9 HUMAN PROGRAM.Landoni EAresu LCapellero SVitali LSangiolo DBerrino ELeuci VGrignani GDe Maria RVigna EDotti GSapino AOlimpo MProment ADonini CAccornero PCesar Conti LMassa AGalvagno FfalseDevelopment and activity of canine B7-H3-CAR.CIK lymphocytes against sarcomas: preclinical evidence and perspectives for human clinical translation.Advanced-stage sarcomas pose a major challenge in oncology, as they are often resistant to conventional therapies and associated with poor prognosis. CAR-based cellular immunotherapy is emerging as a very promising therapeutic option; however, clinically relevant animal models are urgently needed to accelerate the clinical development of these approaches. B7-H3 molecule, due to its low expression in normal tissue, high prevalence in multiple human cancers, and association with cancer stemness and aggressiveness, represents one of the most attractive targets for CAR-immunotherapy. In this study, we established a preclinical cellular immunotherapy platform based on canine cytokine-induced killer cells (CIK) redirected by an antihuman B7-H3 CAR against canine sarcoma cells and 3D sarcoma sphe2025-01-01T00:00:00Z2025 Sep2026-06-01T14:02:02.707Z2026-04-08T13:19:03.718ZS-EPMC124334264094471510.1007/s00262-025-04163-4